Tasocitinib (CP-690,550), an oral Janus kinase inhibitor, significantly improves the symptoms of moderate to severe psoriasis with early onset of efficacy

被引：0

作者：

Harness, Jane ^{[1
]}

Menter, Alan ^{[2
]}

Tan, Huaming ^{[1
]}

Papp, Kim ^{[3
]}

机构：

[1] Pfizer, New London, CT USA

[2] Baylor Res Inst, Dallas, TX USA

[3] Prob Med Res, Waterloo, ON, Canada

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2011年 / 64卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：AB149 / AB149

页数：1

共 50 条

[1] Tasocitinib (CP-690,550), an oral Janus kinase inhibitor, consistently improves the clinical signs of moderate to severe psoriasis in different body regions
Papp, Kim
Menter, Alan
Tan, Huaming
Harness, Jane
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB153 - AB153
[2] An evaluation of the effect of tasocitinib (CP-690,550), an oral Janus kinase inhibitor, on pruritus in patients with plaque psoriasis
Mamolo, Carla
Bushmakin, Andrew
Harness, Jane
Cappelleri, Joseph
Stewart, Michelle
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB146 - AB146
[3] Population pharmacokinetics of tasocitinib (CP-690,550) in patients with moderate to severe plaque psoriasis
Gupta, Pankaj
Harness, Jane
Buonanno, Marjorie
Krishnaswami, Sriram
Chapel, Sunny
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB163 - AB163
[4] Treating inflammation with the Janus Kinase inhibitor CP-690,550
Vijayakrishnan, Lalitha
Venkataramanan, R.
Gulati, Palak
[J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2011, 32 (01) : 25 - 34
[5] A Supratherapeutic Dose of the Janus Kinase Inhibitor Tasocitinib (CP-690,550) Does Not Prolong QTc Interval in Healthy Participants
Krishnaswami, Sriram
Kudlacz, Elizabeth
Wang, Rong
Chan, Gary
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (09): : 1256 - 1263
[6] Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
Tan, H.
Gupta, P.
Harness, J.
Wolk, R.
Chapel, S.
Menter, A.
Strober, B.
Langley, R. G.
Krishnaswami, S.
Papp, K. A.
[J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2013, 2 (05):
[7] THE EFFECT OF ORAL CP-690,550 ON PRURITUS IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
Mamolo, C. M.
Bushmakin, A. G.
Cappelleri, J. C.
Stewart, M.
[J]. VALUE IN HEALTH, 2011, 14 (03) : A56 - A56
[8] Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease
Liew, Shiao Hui
Nichols, Kelly K.
Klamerus, Karen J.
Li, Jim Z.
Zhang, Min
Foulks, Gary N.
[J]. OPHTHALMOLOGY, 2012, 119 (07)
[9] Phase 2 Study of CP-690,550, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
Sandborn, William J.
Ghosh, Subrata
Panes, Julian
Varnic, Ivana
Su, Chinyu
Spanton, J.
Niezychowski, Wojciech
[J]. GASTROENTEROLOGY, 2011, 140 (05) : S110 - S110
[10] The itch severity item: Mediation modeling and measurement characteristics from a phase IIb trial of tasocitinib (CP-690,550), an oral Janus kinase inhibitor, in patients with plaque psoriasis
Mamolo, Carla
Bushmakin, Andrew
Harness, Jane
Cappelleri, Joseph
Stewart, Michelle
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB152 - AB152

← 1 2 3 4 5 →